Literature DB >> 25678097

Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.

Athar A Badar1, Ana C Perez-Moreno, Nathaniel M Hawkins, Alan P T Brunton, Pardeep S Jhund, Chih M Wong, Scott D Solomon, Christopher B Granger, Salim Yusuf, Marc A Pfeffer, Karl Swedberg, Roy S Gardner, Mark C Petrie, John J V McMurray.   

Abstract

AIMS: To investigate the relationship between angina pectoris and fatal and non-fatal clinical outcomes in heart failure with reduced and preserved ejection fraction (HF-REF and HF-PEF, respectively). METHODS AND
RESULTS: Of 7599 patients in the CHARM program, 5408 had ischaemic heart disease; 3855 had HF-REF (ejection fraction ≤45%) and 1553 had HF-PEF. These patients were separated into three groups: no history of angina, previous angina, and current angina. Three coronary outcomes were examined: fatal or non-fatal myocardial infarction (MI); MI or hospitalization for unstable angina (UA); and MI, UA or coronary revascularization. The composite heart failure outcome of cardiovascular death or heart failure hospitalization (HFH) was also analysed, along with its components and all-cause mortality. New York Heart Association functional class was worse in both HF-REF and HF-PEF patients with current angina compared with patients without angina (P < 0.001 and P = 0.005 respectively), despite similar clinical examination findings and ejection fraction. Patients with current angina had a higher risk of all three coronary outcomes (adjusted hazard ratios ranging from 1.8-3.1) than those without angina but did not have a higher risk of heart failure outcomes or all-cause mortality.
CONCLUSION: In patients with heart failure current angina is associated with significantly more functional limitation and a higher risk of coronary events, across the spectrum of left ventricular ejection fraction.
© 2015 The Authors. European Journal of Heart Failure © 2015 European Society of Cardiology.

Entities:  

Keywords:  Angina; Heart failure

Mesh:

Substances:

Year:  2015        PMID: 25678097     DOI: 10.1002/ejhf.221

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  6 in total

Review 1.  End points in heart failure-are we doing it right?

Authors:  Luxitaa Goenka; Melvin George; Sandhiya Selvarajan
Journal:  Eur J Clin Pharmacol       Date:  2017-03-09       Impact factor: 2.953

2.  Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.

Authors:  Jelena P Seferovic; Brian Claggett; Sara B Seidelmann; Ellen W Seely; Milton Packer; Michael R Zile; Jean L Rouleau; Karl Swedberg; Martin Lefkowitz; Victor C Shi; Akshay S Desai; John J V McMurray; Scott D Solomon
Journal:  Lancet Diabetes Endocrinol       Date:  2017-03-18       Impact factor: 32.069

3.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 4.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

Review 5.  Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control.

Authors:  Jelena P Seferovic; Scott D Solomon; Ellen W Seely
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-25       Impact factor: 3.565

6.  Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure.

Authors:  Cassandra Freitas; Xuesong Wang; Yin Ge; Heather J Ross; Peter C Austin; Peter S Pang; Dennis T Ko; Michael E Farkouh; Therese A Stukel; John J V McMurray; Douglas S Lee
Journal:  CJC Open       Date:  2020-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.